Search

Your search keyword '"Kvien, Tore K"' showing total 1,876 results
Start Over Author "Kvien, Tore K"
1,876 results on '"Kvien, Tore K"'

2. T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

Author

Wolf, Asia-Sophia, Bjørlykke, Kristin H., Ørbo, Hilde S., Bhandari, Sabin, Solum, Guri, Kjønstad, Ingrid Fadum, Jyssum, Ingrid, Nygaard, Unni C., Kristoffersen, Anja Bråthen, Christensen, Ingrid E., Josefsson, Sarah E., Lund, Katrine Persgård, Chopra, Adity, Osen, Julie Røkke, Chaban, Viktoriia, Tveter, Anne T., Sexton, Joseph, Kvien, Tore K., Jahnsen, Jørgen, Haavardsholm, Espen A., Grødeland, Gunnveig, Vaage, John Torgils, Provan, Sella A., Kared, Hassen, Lund-Johansen, Fridtjof, Munthe, Ludvig A., Syversen, Silje Watterdal, Goll, Guro Løvik, Jørgensen, Kristin Kaasen, and Mjaaland, Siri

Published
2024
Full Text
View/download PDF

5. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment

Author

Ørnbjerg, Lykke Midtbøll, Brahe, Cecilie Heegaard, Linde, Louise, Jacobsson, Lennart, Nissen, Michael J., Kristianslund, Eirik Klami, Santos, Maria José, Nordström, Dan, Rotar, Ziga, Gudbjornsson, Bjorn, Onen, Fatos, Codreanu, Catalin, Lindström, Ulf, Möller, Burkhard, Kvien, Tore K., Barcelos, Anabela, Eklund, Kari K., Tomšič, Matija, Love, Thorvardur Jon, Can, Gercek, Ionescu, Ruxandra, Loft, Anne Gitte, Mann, Herman, Pavelka, Karel, van de Sande, Marleen, van der Horst-Bruinsma, I.E., Suarez, Manuel Pombo, Sánchez-Piedra, Carlos, Macfarlane, Gary J., Iannone, Florenzo, Michelsen, Brigitte, Hyldstrup, Lise Hejl, Krogh, Niels Steen, Østergaard, Mikkel, and Hetland, Merete Lund

Published
2024
Full Text
View/download PDF

6. Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial

Author

Kjørholt, Kaja E, Sundlisæter, Nina Paulshus, Aga, Anna-Birgitte, Sexton, Joseph, Olsen, Inge C, Fremstad, Hallvard, Spada, Cristina, Madland, Tor Magne, Høili, Christian A, Bakland, Gunnstein, Lexberg, Åse, Hansen, Inger Johanne Widding, Hansen, Inger Myrnes, Haukeland, Hilde, Ljoså, Maud-Kristine Aga, Moholt, Ellen, Uhlig, Till, Kvien, Tore K, Solomon, Daniel H, van der Heijde, Désirée, Haavardsholm, Espen A, and Lillegraven, Siri

Published
2024
Full Text
View/download PDF

7. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

Author

Linde, Louise, Ørnbjerg, Lykke M., Rasmussen, Simon H., Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K., Kvien, Tore K., Rodrigues, Ana M., Santos, Maria J., Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J., Ciurea, Adrian, Macfarlane, Gary J., Heddle, Maureen, Glintborg, Bente, Østergaard, Mikkel, and Hetland, Merete L.

Published
2023
Full Text
View/download PDF

8. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials

Author

Brun, Marthe Kirkesæther, Gehin, Johanna E, Bjørlykke, Kristin Hammersbøen, Warren, David John, Klaasen, Rolf A, Sexton, Joseph, Sandanger, Øystein, Kvien, Tore K, Mørk, Cato, Jahnsen, Jørgen, Bolstad, Nils, Jørgensen, Kristin Kaasen, Haavardsholm, Espen A, Goll, Guro Løvik, and Syversen, Silje Watterdal

Published
2024
Full Text
View/download PDF

9. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies

Author

Lauper, Kim, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, Gottenberg, Jacques-Eric, Kubo, Satoshi, Hetland, Merete Lund, Iannone, Florenzo, Kristianslund, Eirik K., Kvien, Tore K., Lukina, Galina, Mariette, Xavier, Nordström, Dan C., Pavelka, Karel, Pombo-Suarez, Manuel, Rotar, Ziga, Santos, Maria J., Tanaka, Yoshiya, Turesson, Carl, Courvoisier, Delphine S., Finckh, Axel, and Gabay, Cem

Published
2024
Full Text
View/download PDF

14. Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models

Author

Wibetoe, Grunde, Sexton, Joseph, Ikdahl, Eirik, Rollefstad, Silvia, Kitas, George D, van Riel, Piet, Gabriel, Sherine, Kvien, Tore K, Douglas, Karen, Sandoo, Aamer, Arts, Elke E, Wållberg-Jonsson, Solveig, Dahlqvist, Solbritt Rantapää, Karpouzas, George, Dessein, Patrick H, Tsang, Linda, El-Gabalawy, Hani, Hitchon, Carol A, Pascual-Ramos, Virginia, Contreas-Yañes, Irazu, Sfikakis, Petros P, González-Gay, Miguel A, Colunga-Pedraz, Iris J, Galarza-Delgado, Dionicio A, Azpiri-Lopez, Jose Ramon, Crowson, Cynthia S, and Semb, Anne Grete

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Rheumatoid Arthritis, Heart Disease, Autoimmune Disease, Prevention, Arthritis, Aging, Inflammatory and immune system, Good Health and Well Being, Adult, Age Factors, Aged, Arthritis, Rheumatoid, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Risk Assessment, Risk Factors, Cardiovascular risk age, Vascular age, Cardiovascular disease, Risk factors, Rheumatoid arthritis, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

BackgroundIn younger individuals, low absolute risk of cardiovascular disease (CVD) may conceal an increased risk age and relative risk of CVD. Calculation of risk age is proposed as an adjuvant to absolute CVD risk estimation in European guidelines. We aimed to compare the discriminative ability of available risk age models in prediction of CVD in rheumatoid arthritis (RA). Secondly, we also evaluated the performance of risk age models in subgroups based on RA disease characteristics.MethodsRA patients aged 30-70 years were included from an international consortium named A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA). Prior CVD and diabetes mellitus were exclusion criteria. The discriminatory ability of specific risk age models was evaluated using c-statistics and their standard errors after calculating time until fatal or non-fatal CVD or last follow-up.ResultsA total of 1974 patients were included in the main analyses, and 144 events were observed during follow-up, the median follow-up being 5.0 years. The risk age models gave highly correlated results, demonstrating R2 values ranging from 0.87 to 0.97. However, risk age estimations differed > 5 years in 15-32% of patients. C-statistics ranged 0.68-0.72 with standard errors of approximately 0.03. Despite certain RA characteristics being associated with low c-indices, standard errors were high. Restricting analysis to European RA patients yielded similar results.ConclusionsThe cardiovascular risk age and vascular age models have comparable performance in predicting CVD in RA patients. The influence of RA disease characteristics on the predictive ability of these prediction models remains inconclusive.

Published
2020

15. Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients

Author

Roelsgaard, Ida K, Ikdahl, Eirik, Rollefstad, Silvia, Wibetoe, Grunde, Esbensen, Bente A, Kitas, George D, van Riel, Piet, Gabriel, Sherine, Kvien, Tore K, Douglas, Karen, Wållberg-Jonsson, Solveig, Dahlqvist, Solbritt Rantapää, Karpouzas, George, Dessein, Patrick H, Tsang, Linda, El-Gabalawy, Hani, Hitchon, Carol A, Pascual-Ramos, Virginia, Contreras-Yáñez, Irazú, Sfikakis, Petros P, González-Gay, Miguel A, Crowson, Cynthia S, and Semb, Anne Grete

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Tobacco Smoke and Health, Arthritis, Prevention, Cardiovascular, Heart Disease, Tobacco, Clinical Research, Good Health and Well Being, Adult, Aged, Arthritis, Rheumatoid, Blood Pressure, Cardiovascular Diseases, Female, Humans, Lipoproteins, Male, Middle Aged, Risk Factors, Risk Reduction Behavior, Severity of Illness Index, Smoking, Smoking Cessation, rheumatoid arthritis, epidemiology, behaviour, quality of life, outcome measures, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesSmoking is a major risk factor for the development of both cardiovascular disease (CVD) and RA and may cause attenuated responses to anti-rheumatic treatments. Our aim was to compare disease activity, CVD risk factors and CVD event rates across smoking status in RA patients.MethodsDisease characteristics, CVD risk factors and relevant medications were recorded in RA patients without prior CVD from 10 countries (Norway, UK, Netherlands, USA, Sweden, Greece, South Africa, Spain, Canada and Mexico). Information on CVD events was collected. Adjusted analysis of variance, logistic regression and Cox models were applied to compare RA disease activity (DAS28), CVD risk factors and event rates across categories of smoking status.ResultsOf the 3311 RA patients (1012 former, 887 current and 1412 never smokers), 235 experienced CVD events during a median follow-up of 3.5 years (interquartile range 2.5-6.1). At enrolment, current smokers were more likely to have moderate or high disease activity compared with former and never smokers (P

Published
2020

17. Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

Author

Bjørlykke, Kristin H, Ørbo, Hilde S, Tveter, Anne T, Jyssum, Ingrid, Sexton, Joseph, Tran, Trung T, Christensen, Ingrid E, Kro, Grete Birkeland, Kvien, Tore K, Jahnsen, Jørgen, Munthe, Ludvig A, Chopra, Adity, Warren, David J, Mjaaland, Siri, Haavardsholm, Espen A, Grødeland, Gunnveig, Provan, Sella A, Vaage, John T, Syversen, Silje Watterdal, Goll, Guro Løvik, and Jørgensen, Kristin Kaasen

Published
2023
Full Text
View/download PDF

21. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Author

Christensen, Ingrid Egeland, Jyssum, Ingrid, Tveter, Anne Therese, Sexton, Joseph, Tran, Trung T., Mjaaland, Siri, Kro, Grete Birkeland, Kvien, Tore K., Warren, David John, Jahnsen, Jørgen, Munthe, Ludvig A., Haavardsholm, Espen A., Vaage, John Torgils, Grødeland, Gunnveig, Lund-Johansen, Fridtjof, Jørgensen, Kristin Kaasen, Syversen, Silje Watterdal, Goll, Guro Løvik, and Provan, Sella Aarrestad

Published
2022
Full Text
View/download PDF

22. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Author

Jyssum, Ingrid, Kared, Hassen, Tran, Trung T, Tveter, Anne T, Provan, Sella A, Sexton, Joseph, Jørgensen, Kristin K, Jahnsen, Jørgen, Kro, Grete B, Warren, David J, Vaage, Eline B, Kvien, Tore K, Nissen-Meyer, Lise-Sofie H, Anderson, Ane Marie, Grødeland, Gunnveig, Haavardsholm, Espen A, Vaage, John Torgils, Mjaaland, Siri, Syversen, Silje Watterdal, Lund-Johansen, Fridtjof, Munthe, Ludvig A, and Goll, Guro Løvik

Published
2022
Full Text
View/download PDF

23. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis

Author

Crowson, Cynthia S, Rollefstad, Silvia, Ikdahl, Eirik, Kitas, George D, van Riel, Piet LCM, Gabriel, Sherine E, Matteson, Eric L, Kvien, Tore K, Douglas, Karen, Sandoo, Aamer, Arts, Elke, Wållberg-Jonsson, Solveig, Innala, Lena, Karpouzas, George, Dessein, Patrick H, Tsang, Linda, El-Gabalawy, Hani, Hitchon, Carol, Ramos, Virginia Pascual, Yáñez, Irazú Contreras, Sfikakis, Petros P, Zampeli, Evangelia, Gonzalez-Gay, Miguel A, Corrales, Alfonso, Laar, Mart van de, Vonkeman, Harald E, Meek, Inger, and Semb, Anne Grete

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Cardiovascular, Aging, Prevention, Rheumatoid Arthritis, Clinical Research, Heart Disease, Arthritis, Autoimmune Disease, 2.4 Surveillance and distribution, 2.3 Psychological, social and economic factors, Aetiology, Inflammatory and immune system, Good Health and Well Being, Adult, Aged, Arthritis, Rheumatoid, Cardiovascular Diseases, Cholesterol, Cohort Studies, Female, Follow-Up Studies, Humans, Hypertension, Incidence, Male, Middle Aged, Risk Factors, Severity of Illness Index, Sex Factors, Smoking, A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis, Cardiovascular disease, population attributable risk, rheumatoid arthritis, risk factor, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesPatients with rheumatoid arthritis (RA) have an excess risk of cardiovascular disease (CVD). We aimed to assess the impact of CVD risk factors, including potential sex differences, and RA-specific variables on CVD outcome in a large, international cohort of patients with RA.MethodsIn 13 rheumatology centres, data on CVD risk factors and RA characteristics were collected at baseline. CVD outcomes (myocardial infarction, angina, revascularisation, stroke, peripheral vascular disease and CVD death) were collected using standardised definitions.Results5638 patients with RA and no prior CVD were included (mean age: 55.3 (SD: 14.0) years, 76% women). During mean follow-up of 5.8 (SD: 4.4) years, 148 men and 241 women developed a CVD event (10-year cumulative incidence 20.9% and 11.1%, respectively). Men had a higher burden of CVD risk factors, including increased blood pressure, higher total cholesterol and smoking prevalence than women (all p

Published
2018

24. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Author

Smolen, Josef S, Schöls, Monika, Braun, Jürgen, Dougados, Maxime, FitzGerald, Oliver, Gladman, Dafna D, Kavanaugh, Arthur, Landewé, Robert, Mease, Philip, Sieper, Joachim, Stamm, Tanja, Wit, Maarten de, Aletaha, Daniel, Baraliakos, Xenofon, Betteridge, Neil, Bosch, Filip van den, Coates, Laura C, Emery, Paul, Gensler, Lianne S, Gossec, Laure, Helliwell, Philip, Jongkees, Merryn, Kvien, Tore K, Inman, Robert D, McInnes, Iain B, Maccarone, Mara, Machado, Pedro M, Molto, Anna, Ogdie, Alexis, Poddubnyy, Denis, Ritchlin, Christopher, Rudwaleit, Martin, Tanew, Adrian, Thio, Bing, Veale, Douglas, Vlam, Kurt de, and van der Heijde, Désirée

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Arthritis, Autoimmune Disease, Clinical Research, Rare Diseases, Inflammatory and immune system, Advisory Committees, Arthritis, Psoriatic, Axis, Cervical Vertebra, Consensus, Decision Making, Humans, Severity of Illness Index, Spondylitis, Ankylosing, Ankylosing Spondylitis, Outcomes Research, Psoriatic Arthritis, Spondyloarthritis, Treatment, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.

Published
2018

25. ASDAS-CRP and ASDAS-ESR cut-offs for disease activity states in axial spondyloarthritis – Are they interchangeable?

Author

Georgiadis, Stylianos, primary, Ørnbjerg, Lykke Midtbøll, additional, Michelsen, Brigitte, additional, Kvien, Tore K., additional, Di Giuseppe, Daniela, additional, Wallman, Johan K., additional, Závada, Jakub, additional, Provan, Sella A., additional, Kristianslund, Eirik Klami, additional, Rodrigues, Ana Maria, additional, Santos, Maria José, additional, Rotar, Žiga, additional, Pirkmajer, Katja Perdan, additional, Nordström, Dan, additional, Macfarlane, Gary J., additional, Jones, Gareth T., additional, van der Horst-Bruinsma, Irene, additional, Hellamand, Pasoon, additional, Østergaard, Mikkel, additional, and Hetland, Merete Lund, additional

Published
2024
Full Text
View/download PDF

26. Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

Author

Ørbo, Hilde S, primary, Bjørlykke, Kristin H, additional, Sexton, Joseph, additional, Jyssum, Ingrid, additional, Tveter, Anne T, additional, Christensen, Ingrid E, additional, Mjaaland, Siri, additional, Kvien, Tore K, additional, Grødeland, Gunnveig, additional, Kro, Grete B, additional, Jahnsen, Jørgen, additional, Haavardsholm, Espen A, additional, Munthe, Ludvig A, additional, Provan, Sella A, additional, Vaage, John T, additional, Goll, Guro Løvik, additional, Jørgensen, Kristin Kaasen, additional, and Syversen, Silje Watterdal, additional

Published
2024
Full Text
View/download PDF

28. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries.

Author

Crowson, Cynthia S, Gabriel, Sherine E, Semb, Anne Grete, van Riel, Piet LCM, Karpouzas, George, Dessein, Patrick H, Hitchon, Carol, Pascual-Ramos, Virginia, Kitas, George D, Douglas, Karen, Sandoo, Aamer, Rollefstad, Silvia, Ikdahl, Eirik, Kvien, Tore K, Arts, Elke, Fransen, Jaap, Tsang, Linda, El-Gabalawy, Hani, Yáñez, Irazú Contreras, Matteson, Eric L, Rantapää-Dahlqvist, Solbritt, Wållberg-Jonsson, Solveig, Innala, Lena, Sfikakis, Petros P, Zampeli, Evi, Gonzalez-Gay, Miguel A, Corrales, Alfonso, van de Laar, Mart, Vonkeman, Harald, Meek, Inger, Husni, Elaine, Overman, Robert, Colunga, Iris, and Galarza, Dionicio

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Cardiovascular, Heart Disease, Prevention, Arthritis, Clinical Research, Adult, Age Distribution, Aged, Algorithms, Arthritis, Rheumatoid, Canada, Cardiovascular Diseases, Cohort Studies, Comorbidity, Female, Humans, Incidence, Internationality, Male, Mexico, Middle Aged, Netherlands, Norway, Predictive Value of Tests, Prognosis, Risk Assessment, Severity of Illness Index, Sex Distribution, South Africa, United Kingdom, United States, rheumatoid arthritis, cardiovascular disease, risk prediction, risk assessment, Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesCardiovascular disease (CVD) risk calculators developed for the general population do not accurately predict CVD events in patients with RA. We sought to externally validate risk calculators recommended for use in patients with RA including the EULAR 1.5 multiplier, the Expanded Cardiovascular Risk Prediction Score for RA (ERS-RA) and QRISK2.MethodsSeven RA cohorts from UK, Norway, Netherlands, USA, South Africa, Canada and Mexico were combined. Data on baseline CVD risk factors, RA characteristics and CVD outcomes (including myocardial infarction, ischaemic stroke and cardiovascular death) were collected using standardized definitions. Performance of QRISK2, EULAR multiplier and ERS-RA was compared with other risk calculators [American College of Cardiology/American Heart Association (ACC/AHA), Framingham Adult Treatment Panel III Framingham risk score-Adult Treatment Panel (FRS-ATP) and Reynolds Risk Score] using c-statistics and net reclassification index.ResultsAmong 1796 RA patients without prior CVD [mean ( s . d .) age: 54.0 (14.0) years, 74% female], 100 developed CVD events during a mean follow-up of 6.9 years (12430 person-years). Estimated CVD risk by ERS-RA [mean ( s . d .) 8.8% (9.8%)] was comparable to FRS-ATP [mean ( s . d .) 9.1% (8.3%)] and Reynolds [mean ( s . d .) 9.2% (12.2%)], but lower than ACC/AHA [mean ( s . d .) 9.8% (12.1%)]. QRISK2 substantially overestimated risk [mean ( s . d .) 15.5% (13.9%)]. Discrimination was not improved for ERS-RA (c-statistic = 0.69), QRISK2 or EULAR multiplier applied to ACC/AHA compared with ACC/AHA (c-statistic = 0.72 for all) or for FRS-ATP (c-statistic = 0.75). The net reclassification index for ERS-RA was low (-0.8% vs ACC/AHA and 2.3% vs FRS-ATP).ConclusionThe QRISK2, EULAR multiplier and ERS-RA algorithms did not predict CVD risk more accurately in patients with RA than CVD risk calculators developed for the general population.

Published
2017

29. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept:Results from the international TOCERRA and PANABA observational collaborative studies

Author

Lauper, Kim, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, Gottenberg, Jacques Eric, Kubo, Satoshi, Hetland, Merete Lund, Iannone, Florenzo, Kristianslund, Eirik K., Kvien, Tore K., Lukina, Galina, Mariette, Xavier, Nordström, Dan C., Pavelka, Karel, Pombo-Suarez, Manuel, Rotar, Ziga, Santos, Maria J., Tanaka, Yoshiya, Turesson, Carl, Courvoisier, Delphine S., Finckh, Axel, Gabay, Cem, Lauper, Kim, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, Gottenberg, Jacques Eric, Kubo, Satoshi, Hetland, Merete Lund, Iannone, Florenzo, Kristianslund, Eirik K., Kvien, Tore K., Lukina, Galina, Mariette, Xavier, Nordström, Dan C., Pavelka, Karel, Pombo-Suarez, Manuel, Rotar, Ziga, Santos, Maria J., Tanaka, Yoshiya, Turesson, Carl, Courvoisier, Delphine S., Finckh, Axel, and Gabay, Cem

Abstract

Objective To evaluate and compare the use of oral glucocorticoids with three classes of bDMARDs in patients with rheumatoid arthritis (RA). Methods We included patients from 13 observational registries treated with a TNF-inhibitor, abatacept or tocilizumab and with available information on the use of oral glucocorticoids. The main outcome was oral glucocorticoid withdrawal. A McNemar test was used to analyse the change in the use of glucocorticoids after 1 year. Kaplan-Meier estimates and Cox regressions, adjusted for patient, treatment, and disease characteristics, were used to evaluate glucocorticoid discontinuation in patients with glucocorticoids at baseline. Because of heterogeneity, analyses were done by registers and pooled using random-effects meta-analysis. Results A total of 12,334 participants treated with TNF-inhibitors, 2100 with tocilizumab and 3229 with abatacept were included. At one-year, oral glucocorticoid use decreased in all treatment groups (odds ratio for stopping vs. starting of 2.19 [95% CI 1.58; 3.04] for TNF-inhibitors, 2.46 [1.39; 4.35] for tocilizumab; 1.73 [1.25; 2.21] for abatacept). Median time to glucocorticoid withdrawal was ≈2 years or more in most countries, with a gradual decrease over time. Compared to TNF-inhibitors, crude hazard ratios of glucocorticoid discontinuation were 0.65[0.48–0.87] for abatacept, and 1.04 [0.76–1.43] for tocilizumab, and adjusted hazard ratios were 1.1 [0.83–1.47] for abatacept, and 1.30 [0.96–1.78] for tocilizumab. Conclusion After initiation of a bDMARD, glucocorticoid use decreased similarly in all treatment groups. However, glucocorticoid withdrawal was much slower than advocated by current international guidelines. More effort should be devoted to glucocorticoid tapering when low disease activity is achieved., Objective: To evaluate and compare the use of oral glucocorticoids with three classes of bDMARDs in patients with rheumatoid arthritis (RA). Methods: We included patients from 13 observational registries treated with a TNF-inhibitor, abatacept or tocilizumab and with available information on the use of oral glucocorticoids. The main outcome was oral glucocorticoid withdrawal. A McNemar test was used to analyse the change in the use of glucocorticoids after 1 year. Kaplan-Meier estimates and Cox regressions, adjusted for patient, treatment, and disease characteristics, were used to evaluate glucocorticoid discontinuation in patients with glucocorticoids at baseline. Because of heterogeneity, analyses were done by registers and pooled using random-effects meta-analysis. Results: A total of 12,334 participants treated with TNF-inhibitors, 2100 with tocilizumab and 3229 with abatacept were included. At one-year, oral glucocorticoid use decreased in all treatment groups (odds ratio for stopping vs. starting of 2.19 [95% CI 1.58; 3.04] for TNF-inhibitors, 2.46 [1.39; 4.35] for tocilizumab; 1.73 [1.25; 2.21] for abatacept). Median time to glucocorticoid withdrawal was ≈2 years or more in most countries, with a gradual decrease over time. Compared to TNF-inhibitors, crude hazard ratios of glucocorticoid discontinuation were 0.65[0.48–0.87] for abatacept, and 1.04 [0.76–1.43] for tocilizumab, and adjusted hazard ratios were 1.1 [0.83–1.47] for abatacept, and 1.30 [0.96–1.78] for tocilizumab. Conclusion: After initiation of a bDMARD, glucocorticoid use decreased similarly in all treatment groups. However, glucocorticoid withdrawal was much slower than advocated by current international guidelines. More effort should be devoted to glucocorticoid tapering when low disease activity is achieved.

Published
2024

30. Cut-Offs for Disease Activity States in Axial Spondylarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?

Author

Georgiadis, Stylianos, Ørnbjerg, Lykke Midtbøll, Michelsen, Brigitte, Kvien, Tore K., Di Giuseppe, Daniela, Wallman, Johan K., Závada, Jakub, Provan, Sella A., Kristianslund, Eirik Klami, Rodrigues, Ana Maria, Santos, Maria José, Rotar, Žiga, Pirkmajer, Katja Perdan, Nordström, Dan, Macfarlane, Gary J., Jones, Gareth T., van der Horst-Bruinsma, Irene, Hellamand, Pasoon, Østergaard, Mikkel, and Hetland, Merete Lund

Published
2024
Full Text
View/download PDF

31. Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases.

Author

Jyssum, Ingrid, Gehin, Johanna E, Sexton, Joseph, Kristianslund, Eirik Klami, Hu, Yi, Warren, David John, Kvien, Tore K, Haavardsholm, Espen A, Syversen, Silje Watterdal, Bolstad, Nils, and Goll, Guro Løvik

Subjects
ANTI-inflammatory agents, FLUORESCENCE polarization immunoassay, RESEARCH funding, RHEUMATOID arthritis, SCIENTIFIC observation, BLOOD collection, LONG-term health care, IMMUNOGLOBULINS, TREATMENT duration, TREATMENT effectiveness, DESCRIPTIVE statistics, DRUG monitoring, ODDS ratio, ADALIMUMAB, COMPARATIVE studies, CONFIDENCE intervals
Abstract

Objectives To explore associations between serum adalimumab level, treatment response and drug survival in order to identify optimal drug levels for therapeutic drug monitoring of adalimumab. Also, to assess the occurrence and risk factors of anti-drug antibody (ADAb) formation. Methods Non-trough adalimumab and ADAb levels were measured by automated fluorescence assays in serum collected after 3 months of adalimumab treatment in patients with RA, PsA or axial SpA (axSpA) included in the observational NOR-DMARD study. Treatment response was evaluated after 3 months and drug survival was evaluated during long-term follow-up. Results In 340 patients (97 RA, 69 PsA, 174 axSpA), the median adalimumab level was 7.3 mg/l (interquartile range 4.0–10.3). A total of 33 (10%) patients developed ADAbs. Findings were comparable across diagnoses. In RA and PsA, adalimumab levels ≥6.0 mg/l were associated with treatment response [odds ratio (OR) 2.2 (95% CI 1.0, 4.4)] and improved drug survival [hazard ratio 0.49 (95% CI 0.27, 0.80)]. In axSpA, a therapeutic level could not be identified, but higher adalimumab levels were associated with response. Factors associated with ADAb formation were previous bDMARD use, no methotrexate comedication and the use of adalimumab originator compared with GP2017. Conclusion Higher adalimumab levels were associated with a better response and improved drug survival for all diagnoses, with a suggested lower threshold of 6.0 mg/l for RA/PsA. This finding, the large variability in drug levels among patients receiving standard adalimumab dose and the high proportion of patients developing ADAbs encourages further investigations into the potential role of therapeutic drug monitoring of adalimumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

Author

Michelsen, Brigitte, Georgiadis, Stylianos, Di Giuseppe, Daniela, Loft, Anne G., Nissen, Michael J., Iannone, Florenzo, Pombo‐Suarez, Manuel, Mann, Herman, Rotar, Ziga, Eklund, Kari K., Kvien, Tore K., Santos, Maria J., Gudbjornsson, Bjorn, Codreanu, Catalin, Yilmaz, Sema, Wallman, Johan K., Brahe, Cecilie H., Möller, Burkhard, Favalli, Ennio G., Sánchez‐Piedra, Carlos, Nekvindova, Lucie, Tomsic, Matija, Trokovic, Nina, Kristianslund, Eirik K., Santos, Helena, Löve, Thorvardur J., Ionescu, Ruxandra, Pehlivan, Yavuz, Jones, Gareth T., van der Horst‐Bruinsma, Irene, Ørnbjerg, Lykke M., Østergaard, Mikkel, and Hetland, Merete L.

Published
2022
Full Text
View/download PDF

35. T Cell Responses to Repeated SARS-CoV-2 Vaccination and Breakthrough Infections in Patients on TNF Inhibitor Treatment: A Prospective Cohort Study

Author

Wolf, Asia-Sophia, primary, Bjørlykke, Kristin Hammersbøen, additional, Ørbo, Hilde S., additional, Bhandari, Sabin, additional, Solum, Guri, additional, Fadum Kjønstad, Ingrid, additional, Jyssum, Ingrid, additional, Nygaard, Unni C., additional, Kristoffersen, Anja Bråthen, additional, Christensen, Ingrid E., additional, Josefsson, Sarah E., additional, Persgård Lund, Katrine, additional, Chopra, Adity, additional, Tveter, Anne T., additional, Sexton, Joseph, additional, Kvien, Tore K., additional, Jahnsen, Jørgen, additional, Haavardsholm, Espen A., additional, Grødeland, Gunnveig, additional, Vaage, John Torgils, additional, Provan, Sella Aarrestad, additional, Kared, Hassen, additional, Lund-Johansen, Fridtjof, additional, Munthe, Ludvig André, additional, Syversen, Silje Watterdal, additional, Goll, Guro Løvik, additional, Jørgensen, Kristin Kaasen, additional, and Mjaaland, Siri, additional

Published
2024
Full Text
View/download PDF

36. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)

Author

Aymon, Romain, primary, Mongin, Denis, additional, Bergstra, Sytske Anne, additional, Choquette, Denis, additional, Codreanu, Catalin, additional, De Cock, Diederik, additional, Dreyer, Lene, additional, Elkayam, Ori, additional, Huschek, Doreen, additional, Hyrich, Kimme L, additional, Iannone, Florenzo, additional, Inanc, Nevsun, additional, Kearsley-Fleet, Lianne, additional, KOCA, Suleyman Serdar, additional, Kvien, Tore K, additional, Leeb, Burkhard F, additional, Lukina, Galina, additional, Nordström, Dan C, additional, Pavelka, Karel, additional, Pombo-Suarez, Manuel, additional, Rodrigues, Ana, additional, Rotar, Ziga, additional, Strangfeld, Anja, additional, Verschueren, Patrick, additional, Westermann, Rasmus, additional, Zavada, Jakub, additional, Courvoisier, Delphine Sophie, additional, Finckh, Axel, additional, and Lauper, Kim, additional

Published
2023
Full Text
View/download PDF

37. Developing and externally validating multinomial prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: Results from an international collaboration

Author

Gehringer, Celina K., primary, Martin, Glen P., additional, Hyrich, Kimme L., additional, Verstappen, Suzanne M.M., additional, Sexton, Joseph, additional, Kristianslund, Eirik K., additional, Provan, Sella A., additional, Kvien, Tore K., additional, and Sergeant, Jamie C., additional

Published
2023
Full Text
View/download PDF

41. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).

Author

Aymon, Romain, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, De Cock, Diederik, Dreyer, Lene, Elkayam, Ori, Huschek, Doreen, Hyrich, Kimme L., Iannone, Florenzo, Inanc, Nevsun, Kearsley-Fleet, Lianne, KOCA, Suleyman Serdar, Kvien, Tore K., Leeb, Burkhard F., Lukina, Galina, Nordström, Dan C., Pavelka, Karel, and Pombo-Suarez, Manuel

Published
2024
Full Text
View/download PDF

45. Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Author

Jyssum, Ingrid, primary, Gehin, Johanna E, additional, Sexton, Joseph, additional, Kristianslund, Eirik Klami, additional, Hu, Yi, additional, Warren, David John, additional, Kvien, Tore K, additional, Haavardsholm, Espen A, additional, Syversen, Silje Watterdal, additional, Bolstad, Nils, additional, and Goll, Guro Løvik, additional

Published
2023
Full Text
View/download PDF

46. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

Author

Lillegraven, Siri, primary, Paulshus Sundlisæter, Nina, additional, Aga, Anna-Birgitte, additional, Sexton, Joseph, additional, Olsen, Inge Christoffer, additional, Lexberg, Åse Stavland, additional, Madland, Tor Magne, additional, Fremstad, Hallvard, additional, Høili, Christian A., additional, Bakland, Gunnstein, additional, Spada, Cristina, additional, Haukeland, Hilde, additional, Hansen, Inger Myrnes, additional, Moholt, Ellen, additional, Uhlig, Till, additional, Solomon, Daniel H, additional, van der Heijde, Désirée, additional, Kvien, Tore K, additional, and Haavardsholm, Espen A, additional

Published
2023
Full Text
View/download PDF

49. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study

Author

Hoff, Mari, Kvien, Tore K, Kälvesten, Johan, Elden, Aake, Kavanaugh, Arthur, and Haugeberg, Glenn

Abstract

Abstract Background Anti-TNF therapy has been shown to reduce radiographic joint damage in rheumatoid arthritis (RA) independent of clinical response. This has previously not been examined for periarticular bone loss, the other characteristic feature of bone involvement in RA. The objective of this study was to examine if treatment with the TNF-α inhibitor adalimumab also could reduce periarticular bone loss in RA patients independent of disease activity. Methods RA patients were recruited from the PREMIER study and included 214 patients treated with methotrexate (MTX) plus adalimumab and 188 patients treated with MTX monotherapy. Periarticular bone loss was assessed by digital X-ray radiogrammetry metacarpal cortical index (DXR-MCI). Change in DXR-MCI was evaluated in patients with different levels of clinical response, as assessed by changes in DAS28 score at 52 weeks and in mean C-reactive protein (CRP) levels during follow-up. Results In the MTX group, there was a greater median DXR-MCI loss among patients with moderate and high disease activity compared to those in remission or with low disease activity (-3.3% vs. -2.2%, p = 0.01). In contrast, periarticular bone loss was independent of disease activity (-1.9% vs. -2.4%, p = 0.99) in the combination group. In the MTX group patients with a mean CRP of ≥ 10 mg/l lost significantly more DXR-MCI than patients with low CRP (-3.1% vs. -1.9%, p

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results